CytomX Therapeutics Inc
NASDAQ:CTMX
US |
Fubotv Inc
NYSE:FUBO
|
Media
|
|
US |
Bank of America Corp
NYSE:BAC
|
Banking
|
|
US |
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
|
US |
C
|
C3.ai Inc
NYSE:AI
|
Technology
|
US |
Uber Technologies Inc
NYSE:UBER
|
Road & Rail
|
|
CN |
NIO Inc
NYSE:NIO
|
Automobiles
|
|
US |
Fluor Corp
NYSE:FLR
|
Construction
|
|
US |
Jacobs Engineering Group Inc
NYSE:J
|
Professional Services
|
|
US |
TopBuild Corp
NYSE:BLD
|
Consumer products
|
|
US |
Abbott Laboratories
NYSE:ABT
|
Health Care
|
|
US |
Chevron Corp
NYSE:CVX
|
Energy
|
|
US |
Occidental Petroleum Corp
NYSE:OXY
|
Energy
|
|
US |
Matrix Service Co
NASDAQ:MTRX
|
Construction
|
|
US |
Automatic Data Processing Inc
NASDAQ:ADP
|
Technology
|
|
US |
Qualcomm Inc
NASDAQ:QCOM
|
Semiconductors
|
|
US |
Ambarella Inc
NASDAQ:AMBA
|
Semiconductors
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
52 Week Range |
0.8632
5.13
|
Price Target |
|
We'll email you a reminder when the closing price reaches USD.
Choose the stock you wish to monitor with a price alert.
Fubotv Inc
NYSE:FUBO
|
US | |
Bank of America Corp
NYSE:BAC
|
US | |
Palantir Technologies Inc
NYSE:PLTR
|
US | |
C
|
C3.ai Inc
NYSE:AI
|
US |
Uber Technologies Inc
NYSE:UBER
|
US | |
NIO Inc
NYSE:NIO
|
CN | |
Fluor Corp
NYSE:FLR
|
US | |
Jacobs Engineering Group Inc
NYSE:J
|
US | |
TopBuild Corp
NYSE:BLD
|
US | |
Abbott Laboratories
NYSE:ABT
|
US | |
Chevron Corp
NYSE:CVX
|
US | |
Occidental Petroleum Corp
NYSE:OXY
|
US | |
Matrix Service Co
NASDAQ:MTRX
|
US | |
Automatic Data Processing Inc
NASDAQ:ADP
|
US | |
Qualcomm Inc
NASDAQ:QCOM
|
US | |
Ambarella Inc
NASDAQ:AMBA
|
US |
This alert will be permanently deleted.
Intrinsic Value
The intrinsic value of one CTMX stock under the Base Case scenario is 1.18 USD. Compared to the current market price of 0.89 USD, CytomX Therapeutics Inc is Undervalued by 25%.
The Intrinsic Value is calculated as the average of DCF and Relative values:
Valuation Backtest
CytomX Therapeutics Inc
Uncover deeper insights with the Valuation Backtest. Learn how current stock valuations stack up against historical averages to gauge true investment potential.
Start backtest now and learn if your stock is truly undervalued or overvalued!
Stock is trading at its lowest valuation over the past 5 years.
To access the results of this valuation backtest, please register an account with us. Registration is quick and gives you instant access to insights on 3 stocks per week for free.
The backtest for CTMX cannot be conducted due to limitations such as insufficient data or other constraints. Please select a different stock or adjust your settings.
Fundamental Analysis
Select up to 3 indicators:
Select up to 3 indicators:
Months
Months
Months
Months
Select up to 2 periods:
Revenue & Expenses Breakdown
CytomX Therapeutics Inc
Balance Sheet Decomposition
CytomX Therapeutics Inc
Current Assets | 124.2m |
Cash & Short-Term Investments | 117.6m |
Receivables | 3.4m |
Other Current Assets | 3.2m |
Non-Current Assets | 14.8m |
PP&E | 12.1m |
Intangibles | 1.6m |
Other Non-Current Assets | 1.1m |
Current Liabilities | 119.2m |
Accounts Payable | 1.4m |
Accrued Liabilities | 21.7m |
Other Current Liabilities | 96.1m |
Non-Current Liabilities | 43.2m |
Other Non-Current Liabilities | 43.2m |
Earnings Waterfall
CytomX Therapeutics Inc
Revenue
|
126.6m
USD
|
Operating Expenses
|
-119.9m
USD
|
Operating Income
|
6.7m
USD
|
Other Expenses
|
7.1m
USD
|
Net Income
|
13.8m
USD
|
Free Cash Flow Analysis
CytomX Therapeutics Inc
USD | |
Free Cash Flow | USD |
CTMX Profitability Score
Profitability Due Diligence
CytomX Therapeutics Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
Score
CytomX Therapeutics Inc's profitability score is 42/100. The higher the profitability score, the more profitable the company is.
CTMX Solvency Score
Solvency Due Diligence
CytomX Therapeutics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Score
CytomX Therapeutics Inc's solvency score is 46/100. The higher the solvency score, the more solvent the company is.
Wall St
Price Targets
CTMX Price Targets Summary
CytomX Therapeutics Inc
According to Wall Street analysts, the average 1-year price target for CTMX is 5.42 USD with a low forecast of 3.54 USD and a high forecast of 8.4 USD.
Dividends
Current shareholder yield for CTMX is .
Shareholder yield represents the total return a company provides to its shareholders, calculated as the sum of dividend yield, buyback yield, and debt paydown yield. What is shareholder yield?
Ownership
CTMX Insider Trading
Buy and sell transactions by insiders
Period | Sold | Bought | Net |
---|---|---|---|
3 Months |
|
|
|
6 Months |
|
|
|
9 Months |
|
|
|
12 Months |
|
|
|
Profile
Country
Industry
Market Cap
Dividend Yield
Description
CytomX Therapeutics, Inc. engages in the development of antibody therapeutics for the treatment of cancer based on its Probody therapeutic technology platform. The company is headquartered in South San Francisco, California and currently employs 174 full-time employees. The company went IPO on 2015-10-08. The firm is developing a class of investigational conditionally activated therapeutics, based on its Probody technology platform, for the treatment of cancer. Its Probody technology platform is designed to enable conditional activation of antibody-based drugs in the tumor microenvironment while minimizing drug activity in healthy tissues and in circulation. The company has utilized its multi-modality Probody platform to build a pipeline of therapeutics that encompasses six product candidates, four of which are in multiple Phase II clinical studies in nine cancer indications. The company includes the conditionally activated antibody-drug conjugates (ADCs) praluzatamab ravtansine (CX-2009, targeting CD166) and CX-2029 (targeting CD71), and the Probody immune CPIs pacmilimab (CX-072, targeting PD-L1) and BMS-986249 (targeting CTLA-4).
Contact
IPO
Employees
Officers
The intrinsic value of one CTMX stock under the Base Case scenario is 1.18 USD.
Compared to the current market price of 0.89 USD, CytomX Therapeutics Inc is Undervalued by 25%.